AAAAAA

   
Results: 1-25 | 26-49
Results: 1-25/49
ROLE OF THE VACCINIA VIRUS E3L AND K3L GENE-PRODUCTS IN RESCUE OF VSVAND EMCV FROM THE EFFECTS OF IFN-ALPHA
Authors: SHORS ST BEATTIE E PAOLETTI E TARTAGLIA J JACOBS BL
Citation: St. Shors et al., ROLE OF THE VACCINIA VIRUS E3L AND K3L GENE-PRODUCTS IN RESCUE OF VSVAND EMCV FROM THE EFFECTS OF IFN-ALPHA, Journal of interferon & cytokine research, 18(9), 1998, pp. 721-729
CANARYPOX VIRUS-MEDIATED INTERLEUKIN-12 GENE-TRANSFER INTO MURINE MAMMARY ADENOCARCINOMA INDUCES TUMOR SUPPRESSION AND LONG-TERM ANTITUMORAL IMMUNITY
Authors: PUISIEUX I ODIN L POUJOL D MOINGEON P TARTAGLIA J COX W FAVROT M
Citation: I. Puisieux et al., CANARYPOX VIRUS-MEDIATED INTERLEUKIN-12 GENE-TRANSFER INTO MURINE MAMMARY ADENOCARCINOMA INDUCES TUMOR SUPPRESSION AND LONG-TERM ANTITUMORAL IMMUNITY, Human gene therapy, 9(17), 1998, pp. 2481-2492
CANARYPOX VIRUS-BASED VACCINES - PRIME-BOOST STRATEGIES TO INDUCE CELL-MEDIATED AND HUMORAL IMMUNITY AGAINST HIV
Authors: TARTAGLIA J EXCLER JL ELHABIB R LIMBACH K MEIGNIER B PLOTKIN S KLEIN M
Citation: J. Tartaglia et al., CANARYPOX VIRUS-BASED VACCINES - PRIME-BOOST STRATEGIES TO INDUCE CELL-MEDIATED AND HUMORAL IMMUNITY AGAINST HIV, AIDS research and human retroviruses, 14, 1998, pp. 291-298
CROSS-CLADE ENVELOPE GLYCOPROTEIN-160 SPECIFIC CD8(-LYMPHOCYTE RESPONSES IN EARLY HIV TYPE-1 CLADE-B INFECTION() CYTOTOXIC T)
Authors: WILSON SE PEDERSEN SL KUNICH JC WILKINS VL MANN DL MAZZARA GP TARTAGLIA J CELUM CL SHEPPARD HW
Citation: Se. Wilson et al., CROSS-CLADE ENVELOPE GLYCOPROTEIN-160 SPECIFIC CD8(-LYMPHOCYTE RESPONSES IN EARLY HIV TYPE-1 CLADE-B INFECTION() CYTOTOXIC T), AIDS research and human retroviruses, 14(11), 1998, pp. 925-937
EFFICACY EVALUATION OF PRIME-BOOST PROTOCOL - CANARYPOXVIRUS-BASED FELINE IMMUNODEFICIENCY VIRUS (FIV) VACCINE AND INACTIVATED FIV-INFECTEDCELL VACCINE AGAINST HETEROLOGOUS FIV CHALLENGE IN CATS
Authors: TELLIER MC PU RY POLLOCK D VITSKY A TARTAGLIA J PAOLETTI E YAMAMOTO JK
Citation: Mc. Tellier et al., EFFICACY EVALUATION OF PRIME-BOOST PROTOCOL - CANARYPOXVIRUS-BASED FELINE IMMUNODEFICIENCY VIRUS (FIV) VACCINE AND INACTIVATED FIV-INFECTEDCELL VACCINE AGAINST HETEROLOGOUS FIV CHALLENGE IN CATS, AIDS, 12(1), 1998, pp. 11-18
THE MODE OF PRESENTATION AND ROUTE OF ADMINISTRATION ARE CRITICAL FORTHE INDUCTION OF IMMUNE-RESPONSES TO P53 AND ANTITUMOR IMMUNITY
Authors: HURPIN C ROTARIOA C BISCEGLIA H CHEVALIER M TARTAGLIA J ERDILE L
Citation: C. Hurpin et al., THE MODE OF PRESENTATION AND ROUTE OF ADMINISTRATION ARE CRITICAL FORTHE INDUCTION OF IMMUNE-RESPONSES TO P53 AND ANTITUMOR IMMUNITY, Vaccine, 16(2-3), 1998, pp. 208-215
RECOMBINANT VACCINE-INDUCED PROTECTION AGAINST THE HIGHLY PATHOGENIC SIMIAN IMMUNODEFICIENCY VIRUS SIVMAC251 - DEPENDENCE ON ROUTE OF CHALLENGE EXPOSURE
Authors: BENSON J CHOUGNET C ROBERTGUROFF M MONTEFIORI D MARKHAM P SHEARER G GALLO RC CRANAGE M PAOLETTI E LIMBACH K VENZON D TARTAGLIA J FRANCHINI G
Citation: J. Benson et al., RECOMBINANT VACCINE-INDUCED PROTECTION AGAINST THE HIGHLY PATHOGENIC SIMIAN IMMUNODEFICIENCY VIRUS SIVMAC251 - DEPENDENCE ON ROUTE OF CHALLENGE EXPOSURE, Journal of virology, 72(5), 1998, pp. 4170-4182
IMMUNE-RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INDUCEDBY CANARYPOX EXPRESSING HIV-1(MN) GP120, HIV-1(SF2) RECOMBINANT GP120, OR BOTH VACCINES IN SERONEGATIVE ADULTS
Authors: CLEMENTSMANN ML WEINHOLD K MATTHEWS TJ GRAHAM BS GORSE GJ KEEFER MC MCELRATH MJ HSIEH RH MESTECKY J ZOLLAPAZNER S MASCOLA J SCHWARTZ D SILICIANO R COREY L WRIGHT PF BELSHE R DOLIN R JACKSON S XU S FAST P WALKER MC STABLEIN D EXCLER JL TARTAGLIA J DULIEGE AM SINANGIL F PAOLETTI E
Citation: Ml. Clementsmann et al., IMMUNE-RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INDUCEDBY CANARYPOX EXPRESSING HIV-1(MN) GP120, HIV-1(SF2) RECOMBINANT GP120, OR BOTH VACCINES IN SERONEGATIVE ADULTS, The Journal of infectious diseases, 177(5), 1998, pp. 1230-1246
EFFECT OF CANARYPOX VIRUS (ALVAC)-MEDIATED CYTOKINE EXPRESSION ON MURINE PROSTATE TUMOR-GROWTH
Authors: KAWAKITA M RAO GS RITCHEY JK ORNSTEIN DK HUDSON MA TARTAGLIA J PAOLETTI E HUMPHREY PA HARMON TJ RATLIFF TL
Citation: M. Kawakita et al., EFFECT OF CANARYPOX VIRUS (ALVAC)-MEDIATED CYTOKINE EXPRESSION ON MURINE PROSTATE TUMOR-GROWTH, Journal of the National Cancer Institute, 89(6), 1997, pp. 428-436
RESTRICTED SPECIFICITY OF ANTI-V3 ANTIBODIES INDUCED IN HUMANS BY HIVCANDIDATE VACCINES
Authors: COEFFIER E EXCLER JL KIENY MP MEIGNIER B MOSTE C TARTAGLIA J PIALOUX G SALMONCERON D LECLERC C
Citation: E. Coeffier et al., RESTRICTED SPECIFICITY OF ANTI-V3 ANTIBODIES INDUCED IN HUMANS BY HIVCANDIDATE VACCINES, AIDS research and human retroviruses, 13(17), 1997, pp. 1471-1485
VISUAL TOOLS TO THE RESCUE
Authors: TARTAGLIA J
Citation: J. Tartaglia, VISUAL TOOLS TO THE RESCUE, Byte, 22(2), 1997, pp. 92-92
WHEN C++ IS RIGHT
Authors: TARTAGLIA J
Citation: J. Tartaglia, WHEN C++ IS RIGHT, Byte, 22(2), 1997, pp. 93-93
CHALLENGE OF CHIMPANZEES IMMUNIZED WITH A RECOMBINANT CANARYPOX-HIV-1VIRUS
Authors: GIRARD M VANDERRYST E BARRESINOUSSI F NARA P TARTAGLIA J PAOLETTI E BLONDEAU C JENNINGS M VERRIER F MEIGNIER B FULTZ PN
Citation: M. Girard et al., CHALLENGE OF CHIMPANZEES IMMUNIZED WITH A RECOMBINANT CANARYPOX-HIV-1VIRUS, Virology, 232(1), 1997, pp. 98-104
CANINE-DISTEMPER VIRUS (CDV) INFECTION OF FERRETS AS A MODEL FOR TESTING MORBILLIVIRUS VACCINE STRATEGIES - NYVAC-BASED AND ALVAC-BASED CDVRECOMBINANTS PROTECT AGAINST SYMPTOMATIC INFECTION
Authors: STEPHENSEN CB WELTER J THAKER SR TAYLOR J TARTAGLIA J PAOLETTI E
Citation: Cb. Stephensen et al., CANINE-DISTEMPER VIRUS (CDV) INFECTION OF FERRETS AS A MODEL FOR TESTING MORBILLIVIRUS VACCINE STRATEGIES - NYVAC-BASED AND ALVAC-BASED CDVRECOMBINANTS PROTECT AGAINST SYMPTOMATIC INFECTION, Journal of virology, 71(2), 1997, pp. 1506-1513
REPLICATION-DEFECTIVE CANARYPOX (ALVAC) VECTORS EFFECTIVELY ACTIVATE ANTI-HUMAN IMMUNODEFICIENCY VIRUS-1 CYTOTOXIC T-LYMPHOCYTES PRESENT ININFECTED PATIENTS - IMPLICATIONS FOR ANTIGEN-SPECIFIC IMMUNOTHERAPY
Authors: FERRARI G BEREND C OTTINGER J DODGE R BARTLETT J TOSO J MOODY D TARTAGLIA J COX WI PAOLETTI E WEINHOLD KJ
Citation: G. Ferrari et al., REPLICATION-DEFECTIVE CANARYPOX (ALVAC) VECTORS EFFECTIVELY ACTIVATE ANTI-HUMAN IMMUNODEFICIENCY VIRUS-1 CYTOTOXIC T-LYMPHOCYTES PRESENT ININFECTED PATIENTS - IMPLICATIONS FOR ANTIGEN-SPECIFIC IMMUNOTHERAPY, Blood, 90(6), 1997, pp. 2406-2416
HOST-RANGE RESTRICTION OF VACCINIA VIRUS E3L-SPECIFIC DELETION MUTANTS
Authors: BEATTIE E KAUFFMAN EB MARTINEZ H PERKUS ME JACOBS BL PAOLETTI E TARTAGLIA J
Citation: E. Beattie et al., HOST-RANGE RESTRICTION OF VACCINIA VIRUS E3L-SPECIFIC DELETION MUTANTS, Virus genes, 12(1), 1996, pp. 89-94
ATTENUATED POXVIRUS VECTORS AS CARRIERS IN VACCINES AGAINST HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS TYPE-I
Authors: FRANCHINI G BENSON J GALLO R PAOLETTI E TARTAGLIA J
Citation: G. Franchini et al., ATTENUATED POXVIRUS VECTORS AS CARRIERS IN VACCINES AGAINST HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS TYPE-I, AIDS research and human retroviruses, 12(5), 1996, pp. 407-408
MULTIPLE IMMUNIZATIONS WITH ATTENUATED POXVIRUS HIV TYPE-2 RECOMBINANTS AND SUBUNIT BOOSTS REQUIRED FOR PROTECTION OF RHESUS MACAQUES
Authors: MYAGKIKH M ALIPANAH S MARKHAM PD TARTAGLIA J PAOLETTI E GALLO RC FRANCHINI G ROBERTGUROFF M
Citation: M. Myagkikh et al., MULTIPLE IMMUNIZATIONS WITH ATTENUATED POXVIRUS HIV TYPE-2 RECOMBINANTS AND SUBUNIT BOOSTS REQUIRED FOR PROTECTION OF RHESUS MACAQUES, AIDS research and human retroviruses, 12(11), 1996, pp. 985-992
HUMAN SAFETY AND IMMUNOGENICITY OF A CANARYPOX-RABIES GLYCOPROTEIN RECOMBINANT VACCINE - AN ALTERNATIVE POXVIRUS VECTOR SYSTEM
Authors: FRIES LF TARTAGLIA J TAYLOR J KAUFFMAN EK MEIGNIER B PAOLETTI E PLOTKIN S
Citation: Lf. Fries et al., HUMAN SAFETY AND IMMUNOGENICITY OF A CANARYPOX-RABIES GLYCOPROTEIN RECOMBINANT VACCINE - AN ALTERNATIVE POXVIRUS VECTOR SYSTEM, Vaccine, 14(5), 1996, pp. 428-434
P53 AS A TARGET FOR CANCER VACCINES - RECOMBINANT CANARYPOX VIRUS VECTORS EXPRESSING P53 PROTECT MICE AGAINST LETHAL TUMOR-CELL CHALLENGE
Authors: ROTH J DITTMER D REA D TARTAGLIA J PAOLETTI E LEVINE AJ
Citation: J. Roth et al., P53 AS A TARGET FOR CANCER VACCINES - RECOMBINANT CANARYPOX VIRUS VECTORS EXPRESSING P53 PROTECT MICE AGAINST LETHAL TUMOR-CELL CHALLENGE, Proceedings of the National Academy of Sciences of the United Statesof America, 93(10), 1996, pp. 4781-4786
IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 RECOMBINANT CANARYPOX (ALVAC) VACCINE CANDIDATE IN CYNOMOLGUS MONKEYS
Authors: ANDERSSON S MAKITALO B THORSTENSSON R FRANCHINI G TARTAGLIA J LIMBACH K PAOLETTI E PUTKONEN P BIBERFELD G
Citation: S. Andersson et al., IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 RECOMBINANT CANARYPOX (ALVAC) VACCINE CANDIDATE IN CYNOMOLGUS MONKEYS, The Journal of infectious diseases, 174(5), 1996, pp. 977-985
MEMORY CYTOTOXIC T-LYMPHOCYTE RESPONSES IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I (HIV-1)-NEGATIVE VOLUNTEERS IMMUNIZED WITH A RECOMBINANT CANARYPOX EXPRESSING GP160 OF HIV-1 AND BOOSTED WITH A RECOMBINANT GP160
Authors: FLEURY B JANVIER G PIALOUX G BUSEYNE F ROBERTSON MN TARTAGLIA J PAOLETTI E KIENY MP EXCLER JL RIVIERE Y
Citation: B. Fleury et al., MEMORY CYTOTOXIC T-LYMPHOCYTE RESPONSES IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I (HIV-1)-NEGATIVE VOLUNTEERS IMMUNIZED WITH A RECOMBINANT CANARYPOX EXPRESSING GP160 OF HIV-1 AND BOOSTED WITH A RECOMBINANT GP160, The Journal of infectious diseases, 174(4), 1996, pp. 734-738
MAGE-1-SPECIFIC PRECURSOR CYTOTOXIC T-LYMPHOCYTES PRESENT AMONG TUMOR-INFILTRATING LYMPHOCYTES FROM A PATIENT WITH BREAST-CANCER - CHARACTERIZATION AND ANTIGEN-SPECIFIC ACTIVATION
Authors: TOSO JF OEI C OSHIDARI F TARTAGLIA J PAOLETTI E LYERLY HK TALIB S WEINHOLD KJ
Citation: Jf. Toso et al., MAGE-1-SPECIFIC PRECURSOR CYTOTOXIC T-LYMPHOCYTES PRESENT AMONG TUMOR-INFILTRATING LYMPHOCYTES FROM A PATIENT WITH BREAST-CANCER - CHARACTERIZATION AND ANTIGEN-SPECIFIC ACTIVATION, Cancer research, 56(1), 1996, pp. 16-20
HIV-1 RECOMBINANT POXVIRUS VACCINE INDUCES CROSS-PROTECTION AGAINST HIV-2 CHALLENGE IN RHESUS MACAQUES
Authors: ABIMIKU AG FRANCHINI G TARTAGLIA J ALDRICH K MYAGKIKH M MARKHAM PD CHONG PL KLEIN M KIENY MP PAOLETTI E GALLO RC ROBERTGUROFF M
Citation: Ag. Abimiku et al., HIV-1 RECOMBINANT POXVIRUS VACCINE INDUCES CROSS-PROTECTION AGAINST HIV-2 CHALLENGE IN RHESUS MACAQUES, Nature medicine, 1(4), 1995, pp. 321-329
POXVIRUS-BASED VECTORS AS VACCINE CANDIDATES
Authors: PINCUS S TARTAGLIA J PAOLETTI E
Citation: S. Pincus et al., POXVIRUS-BASED VECTORS AS VACCINE CANDIDATES, Biologicals, 23(2), 1995, pp. 159-164
Risultati: 1-25 | 26-49